ARTICLE | Emerging Company Profile
Aslan: A bridge to Phase III
Singapore's Aslan hopes to help partners take neglected molecules to Phase III
October 3, 2011 7:00 AM UTC
Aslan Pharmaceuticals Pte. Ltd. is providing a bridge for partners that have too many early stage assets. The company's business model is to pick up molecules to develop through Phase II proof-of-concept trials. Aslan will then return a Phase III-ready compound to the originator or find a partner to take it to commercialization.
CEO Carl Firth said Aslan is not a fee-for-service business. As opposed to a CRO, the partner would pay nothing up front - all development and manufacturing would be done and paid for by Aslan...